Recently, Pathway to Cures (P2C) -- NBDF's venture philanthropy fund -- announced exciting updates. Click below to read important press releases.
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
Community experts will discuss clinical research studies and why they are essential to the ultra-rare bleeding disorders community.
NBDF has taken the lead on an initiative to develop a National Research Blueprint (NRB), a community-driven journey to shape the future of research together with researchers, the HTC interdisciplinary team, non-profit organizations, government, and industry partners, and, most importantly, people directly affected by bleeding disorders. Our goal is to establish ways to conduct research in the most inclusive, coordinated and efficient manner that includes patients in all stages of research. In this session, we will provide updates on the NRB initiative and how you can get involved.
Research generates the evidence needed to improve treatment, care, and quality of life. Come and find out how to make sure research findings are representative and useful, and why it matters.
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on ultra rare bleeding disorders: hot and new topics in research
NBDF provides free quality education on issues that matter to the bleeding disorders community.This video is on ATHN advancing care for the blood disorders community
My Life, Our Future (MLOF) is a nationwide campaign offering free genetic testing, or genotyping, for people affected by hemophilia.
A research abstract presented at the recent Thrombosis & Haemostasis Summit of North America 2020 Virtual Conference suggested that epidural analgesia may be a safe option for pregnant women with von Willebrand disease (VWD) type 1, provided clotting factors are maintained at certain levels.
